Similarly, circLIFR has been identified as a tumor suppressor in hepatocellular carcinoma by modulating the miR-624-5p and GSK-3β/β-catenin signaling pathway (Yang et al. 2022). This evidence concerns the gene GSK3B and neoplasm.